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ABSTRACT 
Asthma and neurodevelopmental disorders including autism spectrum disorders (ASD) and 
attention deficit hyperactivity disorders (ADHD) are common diseases starting in early 
childhood. The prevalence of both diseases is rising and little is known about the potential 
genetic and environmental risk factors. Therefore, the overall aim of this thesis was to 
investigate the early life risk factors associated with the subsequent development of asthma 
and neurodevelopmental disorders, especially ASD using population- and family-based 
designs.   
In Study I, we investigated the association between parental socioeconomic status (measured 
by income and education), risk of asthma, and patterns of medication dispenses in a large 
population-based cohort of preschool children. We found an age-varying effect on the risk of 
asthma, but no effect on the pattern of medication dispenses by parental income. Parental 
education, however, was negatively associated with asthma regardless of age and positively 
associated with controller medication dispenses.  
In Studies II and III, we evaluated the association between exposure to traffic-related air 
pollution and neurodevelopmental disorders among children born in Stockholm during 1992-
2007. In contrast to previous findings, there was no clear association between air pollution 
during pregnancy or early infancy and subsequent risk of ASD and ADHD. Residual 
confounding from parental socioeconomic status and psychiatric diagnoses can partly explain 
the findings and the differences observed in some subgroups.   
In Study IV, we assessed the association between parental asthma, use of asthma medication 
during pregnancy and the risk of ASD in offspring by comparing cases and controls in the 
general population and within families. Maternal, but not paternal, asthma, was associated 
with a slightly increased risk of ASD, which was neither confounded by familial factors 
shared among half-siblings and cousins nor mediated through use of asthma medications 
during pregnancy.                                                                                                                                                                                                                                                                                                                                       
In conclusion, these collective studies shed light on the relationship between many early life 
risk factors and subsequent risk of asthma and neurodevelopmental disorders. The higher risk 
of incident asthma and lower rate of controller medication dispenses among young children 
with lower parental socioeconomic background warrants clinical attention. Traffic-related air 
pollution, despite being a major concern to the general public, was not associated with ASD 
and ADHD in the Swedish urban setting. Furthermore, the association between maternal 
asthma and offspring ASD appeared to be persistent, suggesting the importance of future 
investigation into potential biological mechanisms.  
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1 Background 
1.1 Asthma 
1.1.1 Disease characteristics 
The word ‘asthma’ (originally from Greek) appeared first in the Corpus Hippocraticum as a 
medical word indicating difficulty breathing or shortness of breath. Today, these are referred 
to asthma-like symptoms. Asthma is currently defined as “a heterogeneous disease, usually 
characterized by chronic airway inflammation” (1).  
The heterogeneity of asthma means that: 1) there is great variation in clinical and 
physiological features; 2) there is no single pathway to disease development (see 1.1.4 
Etiology and risk factors); and 3) there is no common therapy suitable for all patients (see 
1.1.3 Diagnosis and treatment). 
Symptoms of childhood asthma include wheezing, cough, shortness of breath and chest 
tightness (2). Distinct ‘subgroups’ (phenotypes) of asthma with certain observable 
characteristics have been identified. However, there is a lack of a common phenotypic 
definition to sub-categorize asthma patients (3). For example, asthma can be defined as early-
onset/transient, late-onset, persistent (based on the age of onset of wheezing), eosinophil or 
non-eosinophil (based on the presence of airway inflammatory markers), and atopic or non-
atopic (based on the immunoglobulin E [IgE] antibody responses and co-existing allergic 
diseases) among others (3). Since phenotypes are not mutually exclusive, i.e. a patient can 
belong to more than one asthma phenotype, it is challenging to interpret and compare 
research findings.  
1.1.2 Prevalence 
Asthma is one of the most common chronic diseases among children (1). Globally, the 
prevalence of childhood asthma has varied over the past few decades, with some countries 
reaching a plateau or decline in prevalence after decades of increase (see Figure 1) (4-7). 
There is no evidence of a global decline (8). For example, in high-income countries with high 
asthma prevalence, such as the U.K., the U.S., Australia, and New Zealand, plateaus or slight 
decreases in prevalence have been observed. Among Swedish children, asthma prevalence is 
now stabilized at around  10% (9).  In low- and middle-income countries in Africa and Latin 
America, asthma prevalence is lower, but a recent increasing trend has been reported. (4). 
The genetic variations (i.e. heritability) do not seem to simply account for the differences in 
asthma prevalence over time by countries. The role of the environment, possibly associated 
with economic growth, seems to be increasingly meaningful to the development childhood 
asthma. 
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Figure 1. Global trends in prevalence of childhood asthma symptoms by country. From 
Beasley R, et al. Lancet. 2015 Sep 12;386(9998):1075-85. Reproduced with permission from 
Elsevier. 
1.1.3 Diagnosis and treatment 
The diagnosis of asthma is based on the patient’s history of respiratory symptoms, family 
history of asthma or other allergic diseases, physical examination, and diagnostic tests 
including breathing tests for lung function, airway inflammation and responsiveness, as well 
as tests for allergic sensitization. Clinical, pathological and physiological features can vary 
from patient to patient and none of these signs are mandatory for the diagnosis (2). Asthma, 
especially in children under 5 years of age, can be difficult to diagnose because their 
wheezing may be temporary and attributable to colds or other respiratory infections. 
Therefore, prescribing some medications to test the symptom improvement and identifying 
risk factors for asthma and co-existing allergies can be helpful before making the actual 
asthma diagnosis for this age group (1). 
To better manage patients with asthma in a long-term perspective, pharmacological and non-
pharmacological treatments should be involved and follow-up assessment of asthma control 
and exacerbations is important. Pharmacological treatments for asthma include controller 
medications (i.e. inhaled corticosteroids [ICS], leukotriene antagonists [LTRA]), symptom-
reliever medications (i.e. short-acting β2-adrenoceptor agonists [SABA or β2-agonists]), and 
other add-on medications (i.e. long-acting β2-adrenoceptor agonists [LABA], anti-IgE 
monoclonal antibody) for patients with severe persistent asthma. For example, the Swedish 
Pediatric Society recommends a step-wise treatment algorithm for children under 5 years of 
based on the severity of individual symptoms and response to treatment (see Figure 2) (10). 
Non-pharmacological interventions often include prevention and avoidance of risk factors 
such as tobacco smoke and indoor allergens, as well as breathing exercises (1, 11, 12). 
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Monitoring tools including asthma control questionnaires and asthma control tests can also be 
used to help clinicians and patients reach the goal of treatment (13). 
*LABA should be given only to children above 4 years of age. 
Figure 2. Stepwise approach for treating asthma in children under 5 years of age. Modified 
from the guideline for maintenance treatment among children by the Swedish Pediatric 
Society's section of allergy (10). ICS=inhaled corticosteroids; LABA=long-acting β2 
agonists; LTRA=leukotriene antagonists; SABA=short-acting β2 agonists; 
1.1.4 Etiology and risk factors 
Asthma is a disease with multi-factorial etiology. The genetic factors  (heritability) explain 
more than 50% of individual variations in the liability to asthma in the general population 
(14). A recent consortium-based genome-wide association study identified several loci on 
chromosomes 2, 3, 6, 9, 15 and 22 that were associated with asthma at all ages (15). 
However, these could not contribute to all incident cases over the past few decades and 
explain all the variation by geographic locations mentioned previously. A growing body of 
evidence suggests both perinatal and early life environmental factors may play a significant 
role for the prevalence of asthma (summarized in Figure 3) (5, 16). For example, perinatal 
factors including parental age, maternal body mass index (BMI), maternal stress, smoking 
and diet during pregnancy, and adverse birth characteristics such as low birth weight have 
been found to be associated with asthma (17-22). Early life infections, exposure to tobacco 
smoke, air pollution, and other allergens have all been linked to increased risk of asthma in 
childhood and adolescence, whereas dog and farm exposure were found to be negatively 
associated with asthma (20, 23-28).  
Step 1a Step 1b Step 2 Step 3 Step 4 
SABA when needed 
 Low dose of 
Fluticasone / 
LTRA 
periodically 
Low-to-moderate 
dose of ICS / 
LTRA 
continuously 
Low-to-moderate 
dose of ICS 
+LTRA / LABA*  
Moderate-to-high 
dose of ICS  
+LTRA+LABA* 
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Figure 3. Risk factors for childhood asthma at a glance  
Socioeconomic status   
The association between socioeconomic status (SES) and diverse adverse health outcomes 
has been known for decades (29). However, three main issues remain in the research topic of 
SES and asthma in terms of the measurement of SES, plausible explanations and mechanisms 
behind the association, and differences in healthcare service utilization. 
1.1.4.1  Defining and measuring SES  
SES, sometimes referred as “socioeconomic position”, is commonly defined as a combined 
measure of the social status and economic situation of an individual or group. According to a 
recent systematic review, the measurement of SES (or SES proxies) differs widely between 
studies depending on data availability, and geographic and cultural differences (30). For 
example, family income or highest education level attained within the household are 
commonly used measures in studies from Australia, Brazil, Canada, the Netherlands, the 
U.K., and the U.S. (31-35).  Studies from European countries often use occupational 
classifications to measure individual SES (36-39). For example, in a previous study from 
Sweden there was a lower rate of asthma, rhinitis, and IgE sensitization in children whose 
parents had white-collar work compared to those whose parents had blue-collar work (37). 
The type of enrolled medical insurance, frequently used in American studies, is a measure 
which is less often reported from countries with universal health care systems (31, 40). Area-
level and country-level SES measures, for example area deprivation, average household 
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income, or national gross national income, have also been used in previous studies to 
investigate potential effects of SES on asthma (34, 41, 42). In addition to differing 
measurements for SES, a selected measure of SES may vary over time. For example, 
education measures tend to be stable, whereas income can be volatile and fluctuate 
considerably during the life-course of an individual or within a family. The temporal changes 
of income are difficult to capture and have not been studied in terms of asthma incidence 
among young children. Taken together, it is often difficult to make direct comparisons of 
findings between studies.  
1.1.4.2 Explanations on the association between parental SES and childhood asthma 
Of the many SES-associated environmental risk factors for asthma, the hygiene hypothesis 
summarizes some of the key risk factors. This hypothesis attributes the increased incidence of 
asthma and allergic diseases to improved hygiene level, smaller family size, and less 
exposure to microbe-enriched environments during early-life (43, 44). This hypothesis was 
investigated broadly in epidemiological studies and used to explain the patterns of SES and 
childhood asthma prevalence at country level (45). However, it has been challenged recently 
due to an increasing body of evidence (46). For example, the observed decrease or plateau in 
asthma prevalence that has been observed in some cohorts was not seen in other allergic 
diseases including rhinitis and food allergy (47, 48). Children from minority ethnic 
backgrounds in the U.S. and other socioeconomically disadvantaged families in the U.K. 
were found to have higher asthma risk (49-51). Income and education measures may act as 
proxies for certain lifestyle or behavioral factors in these studies. For example, increases in 
exposure to allergens and psychological distress, as well as decreases in access to healthcare 
and  breastfeeding are all correlated with lower parental income, and have been proposed to 
explain the observed association between SES and asthma occurrence and morbidity (5). 
However, it is still difficult to disentangle how measures of lifestyle and behavior factors 
affect SES because they are often correlated with each other, and all information is not 
available on a population level. 
1.1.4.3 Variations in healthcare service utilization on a national level  
As well as being a risk factor for the occurrence of asthma in general population, SES may be 
related to health disparities observed among asthmatic patients (52). On one hand, a 
significant amount of research has shown that SES is associated with differences in 
healthcare service utilization. Several studies from the U.S. have indicated that children with 
low-income or minority family backgrounds received less asthma specialist care, but more 
emergency department visits and hospitalizations (53, 54). A study from an urban setting in 
Canada, which has a universal healthcare system, reported that two-thirds of asthmatic 
children did not receive follow-up care after an emergency department visit (55). On the other 
hand, the amount of emergency and inpatient care can be reduced by improved adherence to 
asthma treatment (56, 57). However, these findings were restricted to rather short 
observational period. The measurement of healthcare utilizations related to preschool asthma 
under a universal healthcare system has not been investigated on national level either.  
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In summary, further evidence on parental SES and childhood asthma is still needed, as is a 
standard SES metric. Whether there is a difference in asthma-related healthcare utilization in 
a universal healthcare system also remains unclear. 
1.2 Neurodevelopmental disorders (NDDs) 
Neurodevelopmental disorders (NDDs) are early onset conditions of behavioral and cognitive 
impairment associated with the maturation and architecture of the central nervous system 
(58). Individuals with NDDs may suffer from mild to severe alterations in general intellectual 
abilities, motor skills, learning, memory, social cognition, executive functioning, language 
and speech. Some NDDs have multifactorial etiologies and affect more males than females 
(59). Examples of commonly researched disorders include autism spectrum disorder (ASD), 
intellectual disabilities (ID), attention deficit hyperactivity disorder (ADHD). Comorbidity 
with other NDDs is also common (58).  
1.2.1 Autism spectrum disorder (ASD) 
1.2.1.1 Clinical characteristics 
ASD is a concept uniting the formerly separate diagnoses of autistic disorder, Asperger 
disorder, and pervasive developmental disorder-not otherwise specified (58, 60). ASD is 
characterized by social communication and interaction difficulties, alongside restricted 
interests and repetitive behaviors causing impairment in adaptive functioning (61, 62). ASD 
is a life-long neurodevelopmental condition and early signs usually present between 18 and 
24 months of age (63, 64). ASD co-occurs with ID, ADHD, social anxiety disorder, as well 
as somatic conditions including epilepsy, sleep disturbances, immune dysregulations, and 
gastrointestinal symptoms (i.e. diarrhea, constipation, and abdominal pain) (65-69).  
1.2.1.2 Prevalence 
Autism was long considered a rare condition and until the end of the 1990s only a few studies 
reported prevalence above 0.5% (70). However, since the year 2000, prevalence estimates 
and diagnoses rates have been rising. A prevalence of at least 1% in the general population is 
currently widely accepted, but some studies report rates of 2-3% (71-73). The development of 
a broader classification of the autism spectrum, growing awareness and knowledge among 
health professionals and rising public concerns have all contributed to this rise in prevalence. 
Still a certain “true” increase of ASD due to environmental changes cannot be excluded (74).  
Unlike asthma, no geographic variation has been reported for the prevalence of ASD (75).  
Population-based studies in the U.K., the U.S., Sweden, Japan and Korea reported ASD 
prevalence between 1-2% among children (71, 72, 76-78). By contrast, very few prevalence 
studies have been conducted in low- and middle-income countries (75). Furthermore, a strong 
gender bias in ASD prevalence towards males (approximately 4:1) is observed with striking 
consistency. 
 7 
 
1.2.1.3 Etiology and risk factors  
The etiology of ASD is unclear (79). Approximately 10% of cases of ASD are attributable to 
known genetic causes, such as Down’s syndrome and fragile X syndrome. Other genetic and 
non-genetic (environmental) risk factors, as well as interactions between genes and 
environments are thought to explain the majority of cases (80). 
The genetic perspective 
Earlier twin and family studies suggested a high (≥70%) heritability of ASD (81-83). 
However, recent findings suggest that the heritability might be at around 50% and that 
environmental components play a substantial role (84-86). Previous genome-wide association 
studies have identified many loci of small effect, but study sample sizes were limited (87, 
88). Some other studies have also demonstrated copy number variations and de novo 
mutations as important genetic components for ASD(89). The majority of these mutations 
were explained by advanced paternal age (90)  
The environmental perspective 
A variety of environmental risk factors for ASD comprising pre-, peri- and post-natal 
exposures to infections, chemical substances, developmental characteristics, and other social-
demographic influences have been examined in the past decades and contributed to the field 
progress (See Table 1). On one hand, some environmental exposures (e.g. infections) may 
alter the development of the immune system and the central nervous system and be 
subsequently associated with a broader range of neurodevelopmental deficits (69, 91, 92). On 
the other hand, inconsistencies and controversial findings are also reported concerning the 
role of some environmental factors such as ambient air pollution in the etiology of ASD. 
Exposure to air pollution, known to be a major public health concern, often varies by 
ethnicity and other measurements of SES (93). In some metropolitan cities in the U.S., 
households with lower SES are more likely to reside in inner-city locations where lower 
quality housing services (i.e. physical structure of the building, neighborhoods, and 
infrastructure) are offered. However, in Stockholm, people with lower SES tend to live in 
suburbs and are less frequently exposed to traffic-related air pollution than those with higher 
SES (94). Therefore, the way of characterizing SES deserves deliberate consideration and 
may act as a potential source of imprecisely-adjusted confounders (often referred to as 
residual confounding) for the potential association between ambient air pollution and ASD. 
1.2.1.4 Air pollution as a risk factor for ASD 
Exposure to ambient air pollution has been related to a variety of adverse health outcomes, 
primarily diseases of the cardiovascular and respiratory systems (95). Ambient air pollutants 
consists of a mixture of different components from different sources, some commonly used 
markers include particulate matter (PM), nitrogen oxides (NOx), ozone (O3), carbon 
monoxide (CO) and sulfur dioxide (SO2). PM is a mixture of solid and liquid particles 
suspended in air, some of which are also inhalable and could induce physiological and  
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Table 1. A list of identified environmental risk factors for ASD with estimated associations. 
Factors Association 
Socio-demographic, developmental, lifestyle 
Age 
 
Gender – male Positive (96) 
Season of conception Various (97, 98) 
Advanced parental age Positive (99, 100) 
Parental alcohol and drug addiction/misuse Positive (101) 
Parental ethnicity and migration Inconclusive (102-104) 
Maternal obesity Positive (105) 
Urbanicity Positive (106) 
SES Inconclusive (65, 107-109) 
Restricted fetal growth, and other birth 
characteristics 
Positive (110) 
Infections  
Maternal infection during pregnancy 
 
 
ater al i fecti  ri  re a c  Positive (111, 112) 
Early childhood infection 
M 
Positive (113) 
Parental medical conditions   
Parental auto-immune disorders Positive (114, 115) 
Pregnancy complications (not specific to one) Positive (116) 
Maternal asthma and allergies Inconclusive (115, 117, 118) 
Medication use  
Antidepressant  Inconclusive (119-121)   
Asthma medications (terbutaline here) Positive (122)  
Pollutants-related  
Ambient air pollution Inconclusive (123-127)  
Pesticides Positive (128, 129) 
PVC flooring Positive (130) 
Diet and nutrients  
Maternal vitamin D intake Negative (131, 132) 
Maternal fatty acid intake Negative (133) 
Maternal folic acid intake Negative (134, 135) 
  
pathological responses (136). Common indicators for PM usually refer to particles with 
diameters <10 µm (PM10), with diameters between 2.5 and 10 µm (PMcoarse), fine particles 
with diameters <2.5 µm (PM2.5), and ultrafine particles with diameters <0.1 µm (PM0.1) based 
on sizes of particles. Local PM10 in Stockholm primarily originates from road dust related to 
road traffic but the influence of long range transport is also substantial. The concentrations of 
PM10 can vary by season depending on meteorological conditions. The urban background 
level for PM10 has dropped 10% since mid of 1990s. However, many streets within the 
Stockholm city still have higher pollutant levels than current air quality guidelines (20 µg/m
3
) 
(137, 138). NOx consists mainly of nitrogen monoxide (NO) and nitrogen dioxide (NO2), and 
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is often used as a marker of the exhaust originating from road traffic. The proportion of NO 
and NO2 in the air depends on the intensity of sunshine and the levels of ozone.  
Exposure to air pollution in urban areas has been associated with several adverse health 
effects in children, including asthma, allergies and lung function disturbances (139, 140). 
Recent studies have investigated the role of ambient air pollutants including O3, CO, NOx, 
SO2, PM, metals, and other hazardous air pollutants on the development of ASD (Table 2). 
All studies considered exposure during the perinatal period, and ASD were assessed from 
doctor diagnoses, and/or questionnaire-based autistic traits. Windham and colleagues from 
California, the U. S. first reported a positive association between prenatal exposure to PM10 
and ASD (141), which has been replicated in further studies from North Carolina, the U.S., 
and Taiwan (123, 126, 142, 143). However, Raz et al. did not find any PM10-associated ASD 
risk, but a positive association between PM2.5 and ASD (126). Guxens et al. did not find any 
association of PM10, PMcoarse, orPM2.5 and autistic traits (125). Three studies have also 
observed a trimester-specific effect of PM10 (123, 126, 127). For example, a 34-40% 
increased risk of ASD was observed in one study with a higher PM10 level during 3
rd
 
trimester, after adjustment for other exposure periods (123). Only one study has investigated 
the effect on NOx with null findings (125), but three other studies reported NO2-associated 
ASD risks (124, 127, 142). To sum up, the evidence linking ambient air pollution exposure to 
ASD is not consistent and the role of residual confounding, certain pollutants, and specific 
timing of exposure should be further explored.  
Table 2. Short summary on different types of pollutants from recent publications on ASD and 
air pollution.  
Studies                            Pollutants O3 CO NOx SO2 PM Metals* HAP
#
 
Windham GC et al, 2006 (141)  
    
Yes Yes Yes 
Palmer RF et al, 2009 (142) 
     
Yes 
 
Kalkbrenner AE et al, 2010 (143) 
    
Yes Yes Yes 
Volk HE et al, 2013 (127) Yes 
 
Yes 
 
Yes 
  
Becerra TA et al, 2013 (124) Yes Yes Yes 
 
Yes 
  
Jung CR et al, 2013 (144) Yes Yes Yes Yes Yes 
  
Kalkbrenner AE et al, 2015 (123) 
    
Yes 
  
Raz R et al, 2015 (126) 
    
Yes 
  
Guxens M et al, 2016 (125) 
  
Yes 
 
Yes 
  
Note: O3 = ozone, CO = carbon monoxide, NOx = nitrogen oxides, SO2 = sulfur dioxide, and PM = 
particulate matter. *Metals include antimony, beryllium, cadmium, chromium, lead, manganese, 
mercury, and nickel. 
#
 Hazardous air pollutants (i.e. HAPs) include hazardous air pollutants listed on 
Environmental Protection Agency's air toxics website. 
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1.2.1.5 Parental asthma as a risk factor for ASD 
An increasing body of literature has described the potential role of dysregulated immune 
systems and activated inflammation pathways in the central nervous system among patients 
with ASD (69, 91). For example, several studies have described abnormal B-cell, T-cell, and 
NK-cell functions, elevated cytokine responses, decreased immunoglobulin levels, and 
increased autoantibody production among individuals with ASD (145-149). Other studies 
have also proposed that asthma and other immune-mediated diseases may be comorbid with 
ASD (150-152) , or have a higher prevalence among family members of children with ASD 
(117, 153, 154). However, this evidence was based on relatively small clinical samples and 
systematic investigations of the common etiology of immune-mediated diseases and ASD are 
still needed to provide a better understanding of autism.  
Parental asthma, especially maternal asthma which also complicates pregnancy, has been 
associated with poor birth characteristics including smaller size for gestational age, low birth 
weight, and congenital malformations (155). Very few studies have addressed the long-term 
consequences in offspring, for example the occurrence of ASD in offspring born to parents 
with asthma (114, 115, 117, 118, 156, 157). Two studies have indicated that maternal asthma 
may be a risk factor for ASD (114, 117), the rest have reported an association with only one 
subtype of ASD (118) or no association (115). However, there is limited evidence to suggest 
that paternal asthma is not associated with ASD risk (130, 156).  
There are two possible hypotheses for the association between parental asthma and offspring 
ASD. First, the association could be due to shared environmental and/or genetic factors (i.e. 
familial aggregation of asthma and ASD) within the family. For example, shared 
environmental factors including maternal nutrient intake (133, 158-162), infections (111, 
163), as well as other pregnancy and delivery complications (164-167) have been linked to 
maternal asthma and offspring ASD. Shared genetic factors could be the explanation if the 
effects of maternal and paternal asthma on ASD risk are equivalent. Second, the association 
may be due to unique environmental exposures related to asthma, such as asthma medication 
use during pregnancy. Previous studies have suggested a link between in utero exposure to 
β2-agonists, ASD and other developmental disorders in offspring (122, 168, 169). This may 
be caused by over-stimulating the β2-adrenergic receptor during gestation and altering the 
fetal neurodevelopment (170, 171).  Thus, there is reason to believe that familial aggregation 
of asthma and ASD can be attributed to maternal use of β2-agonists during pregnancy. 
1.2.1 Attention Deficit Hyperactivity Disorder (ADHD) 
ADHD is one of the most common NDDs and often characterized by symptoms of 
inattention, and hyperactivity/impulsivity and with an age-of-onset prior to 12 years, 
according to the Diagnostic Manual of Mental Disorders, 5
th
 edition (DSM-5) classification 
(172). The prevalence of ADHD is around 5% in children worldwide (with male 
predominantly) and does not seem to vary by locations (173). Like other complex disorders, 
the etiology of ADHD is not clear. Genetic, early environmental factors and gene-
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environmental interaction can possibly contribute to the ADHD risk. The comorbidity with 
other NDDs such as ASD, motor disorders, and other behavioral problems is frequent (174). 
1.2.2 Intellectual Disability (ID) 
ID is characterized by low general intellectual capacities (IQ < 70) causing significant 
difficulties in adaptive functioning (175). The diagnoses of ID based on ICD-10 and DSM-IV 
classification systems are widely used and the levels of severity are dependent on the IQ 
score (175, 176). Approximately 0.5 to 3% of children are affected by ID, but estimates vary 
by country, study design, age, gender, severity, and parental SES (177, 178). In terms of 
etiology, genetic factors play an important role in ID, but recent studies have found pre- and 
peri-natal factors as well as other environmental exposures can also be linked to increased 
risk of ID (179, 180). Furthermore, ID can occur with or without congenital malformations, 
neurological disorders such as epilepsy, or other NDDs including ASD and ADHD.
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2 Aims 
This thesis explores the contribution of population and family studies to the understanding of 
the etiology of asthma and ASD. 
In particular, we aim: 
 to explore the association of parental SES and the risk of asthma, as well as the  
patterns of medication intake in a nationwide register-based cohort of preschool 
children (Study I); 
 
 to explore the risk of ASD in relation to traffic-related air pollution exposure during 
fetal and early life (Studies II & III); 
 
 to investigate the association between parental asthma, maternal asthma medication 
and risk of ASD in offspring, and whether it is confounded by familial factors 
(Study IV); 
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3 Materials and Methods 
All data obtained from registers and used in all studies are discussed in this chapter. Sweden 
and the other Nordic countries offer unique opportunities for population-based observational 
researches using the rich and high-quality register-based data. The register data include 
individual information from pregnancy and birth, to disease onset such as asthma, migration, 
and death and can be retrieved prospectively or retrospectively.  
3.1 Register data 
Sweden, as well as other Nordic countries, has a long tradition of providing population 
statistical information covering different subjects of interest (demographic, economic, 
business etc.). The earliest uses of administrative data within local parishes date back to the 
18
th
 century, while modern uses began in the1940s when personal identification numbers 
(PIN) were introduced in Sweden (Figure 4) (181). To collect information on a certain unit 
level (e.g. marriage and divorce of citizens and residents, air pollution levels in municipalities 
in Stockholm), and then store, and record the information longitudinally, registers are 
generated and operated by national and regional authorities. Today there are more than 50 
national registers at Statistics Sweden and the National Board of Health and Welfare covering 
individual health and activity data across the lifespan (182).  
Ideally, register data should be as accurate as possible and with comprehensive coverage for 
the purpose of statistical analysis and the generalizability of findings. However, incomplete 
registers can still be useful for certain research purposes. 
3.1.1 Personal identification numbers (PIN) 
All persons who are legally registered in Sweden have been assigned a PIN (personnummer 
in Swedish) since 1947. Immigrants who become permanent residents or intend to stay in 
Sweden for more than 365 days are also assigned a PIN (181).  
The PIN consists of a person’s date of birth, a birth number and a check digit. It is a unique 
identifier of a person except for some rare cases. For example, a PIN can be re-used on an 
immigrant from another deceased person. A change of PIN can also happen when the date of 
birth or sex was incorrectly assigned to immigrants or newborns. Thus, in order to interlink 
register data and avoid the potential pitfalls due to reuses/changes of PIN, two individuals 
with the same PIN are assigned different random serial numbers and an individual with more 
than one PIN during his or her life will have only one serial number for research purposes.   
3.1.2 National registers 
Total Population Register  
The Total Population Register (TPR) was established in 1968 by Statistics Sweden and has 
been used as a sample basis to provide information on the population and its changes (Figure 
4). Today, the TPR includes more than 9 million residents who registered in Sweden at the 
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date of birth or immigration at the Swedish Tax Agency. Information about births, deaths, 
immigration and emigrations, changes in civil status and citizenship is also present in the 
TPR.  
 
Figure 4. Register and Small Area Data from Statistics Sweden 
Multi-Generation Register  
The Multi-Generation Register (MGR) was established in 1961 by Statistics Sweden and 
includes information on all residents who were born in Sweden in 1932 or later or came to 
Sweden after 1947 (referred to as “index persons”) (Figure 4). The MGR has been created on 
the basis of TPR data and has excellent coverage since maternal information (biological or 
adoptive) is available on 100% of index persons born after 1961 and paternal information is 
available for approximately 98% (183). The register can therefore be used to identify family 
members of the index persons such as parents, children, siblings, cousin, etc. With the use of 
PINs, other information can be retrieved via linkages with other registers.  
Longitudinal integration database for health insurance and labor market studies  
The longitudinal integration database for health insurance and labor market studies 
(LISA by Swedish acronym) is a register-based longitudinal database operated by Statistics 
Sweden (Figure 4). It includes socioeconomic information about Swedish households from 
1990 onwards as an upgrade of the national population and housing censuses (1960-1990, 
with approximate 5-year intervals). Existing data on education, income, occupation and 
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employment, for all individuals above 16 years old from different registers in Statistics 
Sweden is integrated by linking individuals to workplaces and educational institutions on a 
yearly basis.  
Cause-of-Death Register 
The Cause-of-Death Register (CDR) contains information from 1961 on all deceased people 
who were registered in Sweden at the time of death (Figure 5). The CDR also includes data 
about the place of death - whether in Sweden or abroad (184). In approximately 1-2% of all 
deaths, the National Board of Health and Welfare could not obtain a death certificate, but 
death records are retained in the CDR without medical information. The underlying cause of 
death is coded using the International Classification of Diseases, 7
th
-10
th
 revisions (ICD-7 to-
10). However, stillbirths and non-residents who died in Sweden are not included in the CDR. 
 
Figure 5. Register data from the National Board of Health and Welfare. 
National Patient Register 
The National Patient Register (NPR) was founded by the National Board of Health and 
Welfare to collect data on individuals who were hospitalized due to somatic diseases in 
Sweden between 1964 and1965 (Figure 5). Psychiatric inpatient care was archived from the 
early 1970s. Visits or day-surgeries at outpatient care clinics were included in 1997 and 2001, 
respectively. However, primary healthcare visits are still provided at the county council level 
and not yet included in the NPR. 
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Information on primary and secondary diagnoses, date of hospital admission and discharge 
from inpatient care, or date of visit from outpatient care is recorded in the NPR. Diagnoses 
are coded based on the Swedish adaption of ICD-7 through -10. The coverage of inpatient 
care has been considered to be 85% by 1983, and almost 100% by 1987; however, coverage 
of outpatient care is approximately 80% due to the lack of information on private 
clinics/hospitals (185).  
Medical Birth Register 
The Medical Birth Register (MBR), initiated in 1973 by the National Board of Health and 
Welfare, contains extensive information on pregnancies, deliveries and newborn (including 
stillbirths with more than 28 weeks of gestational age) infants in Sweden (Figure 5). A 
delivery record must be present in order to be included in the MBR, however medical records 
from antenatal and neonatal care can be missing. Thus, the quality of different variables in the 
MBR varies. Currently, more than 97% of all births by women residing in Sweden are 
included in the MBR (186).  
Prescribed Drug Register 
The Prescribed Drug Register (PDR) contains information on the dispensed medications 
from individual purchases at all pharmacies in Sweden since July 1, 2005 (Figure 5). All 
medications are coded based on the Anatomical Therapeutic Chemical (ATC) classification 
system. The Swedish Pharmacy service company (Apotekens Service AB) takes the 
responsibility of uploading all the information about the purchases (patient, medication, 
prescriber, and pharmacy) to the National Board of Health and Welfare each month. The 
register does not include the indication from the prescription to the patient, but a linkage to 
other registers (e.g. the NPR) via PIN can provide a possibility to explore medication and 
disease associations.  
3.1.3 Regional registers 
The Stockholm regional health care data warehouse (VAL by Swedish acronym) is a 
regional healthcare-related register including approximately 3 million residents in Stockholm 
County (Figure 6). Individual records from hospital visits (inpatient, outpatient, and 
emergency) and primary healthcare centers have been reported to Stockholm County Council 
for administrative and monitoring purposes since 2003. This register provides an additional 
source of individual diagnoses from the NPR.  However, quality check of the data has not 
been performed (187). 
The clinical database for child and adolescent psychiatry in Stockholm County 
(PASTILL by Swedish acronym) is a regional register, including information on child and 
adolescent psychiatric inpatient and outpatient care within Stockholm County since 2000 
(Figure 6). Diagnoses are coded using the Diagnostic and Statistical Manual of Mental 
Disorders, 4th Edition (DSM-IV) until 2008 and the ICD-10 since 2009 (188).  
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Figure 6. Register data from the Stockholm County Council 
The habilitation register (HAB by Swedish acronym) is a regional register recording the 
habilitation services provided by the Stockholm County to children and adolescents with 
disabilities and their families since 1998 (Figure 6). Services are provided free of charge by 
the municipality to those with an established diagnosis such as ASD and ID.  
The emission database (NOx and PM) in Stockholm 
The emission database is administrated by the Stockholm Air Quality and Noise Analysis of 
the Environment and Health Protection Administration in Stockholm. Since 1993, the 
database has been updated on a yearly basis and provides detailed information on emissions 
from sources including road, air and ferry traffic, residential heating, and construction dusts 
(189). 
3.1.4 The Swedish Twin Registry 
The Swedish Twin Registry was started in the1960s and consists of about 95,000 twin pairs. 
It contains invaluable information on twins’ genetic and environmental exposures and various 
health outcomes collected from more than 30 research projects (190-192).The register is 
currently administrated by the Department of Medical Epidemiology and Biostatistics at 
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Karolinska Institute. Of particular interest in the current thesis is the Child and Adolescent 
Twin Study in Sweden (CATSS), an ongoing longitudinal twin study in the STR (193). More 
detailed information about CATSS is described in the method section. 
3.2 General aspects on causal inference  
A central question that motivates many empirical studies in medical sciences is about 
causality (sometimes referred as causation or causal relationship). For example, is there any 
efficacy of a medication in children below 5 years of age? How many asthma cases could 
have been avoided by reducing air pollution levels? Due to the counterfactual issue of causal 
inference (194), a well-designed randomized controlled trial (RCT) is considered a powerful 
methodology to investigate the causal relationship. RCTs provide excellent internal validity 
(i.e. no confounding and selection bias) and more precise efficacy measure of certain 
intervention under ideal conditions. However, some pitfalls of RCTs should not be ignored in 
terms of limited external validity, rare outcomes, costs, time, and ethical issues. For example, 
pregnant women and participants with comorbidities are often excluded in RCTs. Even if 
there is causal relationship, the effect may be limited to a subgroup or during a short follow-
up period. In the case of investigating effects of air pollution exposure, researchers cannot 
assign random selected participants to some residential areas with either high or low pollution 
level.  
Given the limitations of RCTs, epidemiologists can also suggest potential causal inference 
based on observational studies. Examples include analyses of population-based data which 
have shown a relationship between maternal smoking during pregnancy and childhood 
asthma (195), air pollution and lung cancer (196), and socioeconomic status and 
psychopathology (197).  However, making causal inferences based on findings generated 
from observational data can be challenging. One challenge is that we cannot be confident the 
exposed group is the representative of what would have happened to the non-exposed group 
if they had been exposed without randomization. Therefore, important limitations of 
observational studies such as confounding, loss of follow-up, reverse causation, recall bias, 
selection and measurement bias should be discussed when interpreting observed association.  
A range of methods can be applied to account for some of the issues in observational studies, 
but I will describe two methods in this thesis. First, the causal diagram can help to carefully 
identify potential confounders with a priori knowledge about the causal network of exposure, 
outcome, and other covariates (198). Second, the family-based quasi-experimental design 
may tackle some confounding factors shared within families (199).  
Directed acyclic graphs (DAGs) can be used to illustrate briefly the casual diagram. In Figure 
7, the research question investigating whether there is an association between maternal 
asthma (exposure) and offspring ASD (outcome) is presented as the blue arrow with a certain 
direction. A confounder, defined as a variable that is associated with exposure and outcome 
to a certain direction, can be measured or unmeasured. An example of an unmeasured 
confounder here is the genetic susceptibility for maternal asthma and offspring ASD in study 
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IV. Adjustment for (also referred as conditioning on or controlling for) maternal age or 
genetic susceptibility can close the causal path of Exposure  Confounder  Outcome. The 
association can be mediated by some factors (called mediators), e.g. pregnancy and delivery 
complications. Adjustment for mediators can block the causal path of Exposure  Mediators 
 Outcome, and the direct path between Exposure and Outcome can be estimated. In some 
conditions, the effect of exposure on outcome may vary across strata of a third variable 
(called effect modifier). This can be handled by an interaction term in the statistical model.  
 
Figure 7. An example causal diagram using directed acyclic graphs. 
3.3 Study I 
3.3.1 Study population and measures 
In this population-based cohort study, we included all children born in Sweden between April 
1, 2006 and December 31, 2008 (n=288, 872) from the MBR and followed from birth to 
December 31, 2010. Parents’ PINs were retrieved from the MGR. In order to ensure complete 
information on an individual’s highest attained level of education, we excluded children of 
parents who were born abroad and migrated to Sweden after 15 years of age (n = 77,352, 
26.8%). 
Sweden has a universal healthcare system, which aims to ensure that all citizens receive 
health services as needed without financial difficulty to pay for. More than 80% of total 
expenditure on healthcare in Sweden is funded by government (i.e. county councils, local 
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authorities and municipalities). Examples of public-financed healthcare services include 
primary healthcare, hospital inpatient care, outpatient specialized care, emergency care, 
patient transport support, home care, dental care for children and young adults, public health 
and preventive services, inpatient and outpatient prescription medications, disability support 
and rehabilitation services. Swedish citizens, long-term residents, adult asylum seekers, 
asylum-seeking and undocumented children have equal access to healthcare services through 
the universal healthcare system. In addition, In addition, there are two types of private 
healthcare services available for patients, depending on whether they are under contract with 
the National Healthcare Services or not. About 16 % of the total health expenditure is directly 
paid by patients (200), the majority of which is for medications (201). Patient fees per 
outpatient/emergency care visit vary from 200 to 350 SEK, and fees per primary healthcare 
visit and hospital stay per day are cheaper, from 80 up to 200 SEK. Additionally, there is a 
ceiling cost set by the National Board of Health and Social Welfare for patients to limit their 
expenditure on hospital visit (up to 1,100 SEK) and medications (up to 2,200 SEK) (202) .  
Therefore, two common care-seeking pathways for children with asthma symptoms are via 
contact with primary healthcare centers, occasionally followed by referral to hospital in- or 
outpatient care, and via direct contact with hospital inpatient care. Two ways of measuring 
incident asthma were suggested accordingly: 
1. From the NPR, we identified patients with asthma from hospital inpatient or outpatient 
care by the date of first hospital admission or outpatient care visit containing a primary 
diagnosis of asthma, according to the diagnostic codes (J45-J46) of ICD-10. We also 
estimated time to the next inpatient care visit after the first asthma diagnosis based on time 
from the first visit at inpatient (discharge date) or outpatient (visit date) care to the date of the 
next admission to in-patient care with an asthma diagnosis. 
2. From the PDR, patients actively treated with asthma medications were identified. To 
compensate for the lack of diagnostic information from primary healthcare, incident asthma 
was defined based on the date of first filled prescription of ICS, β2 agonists, fixed-dose 
combination of ICS and β2 agonists, and LTRA (by ATC codes R03AC, R03AK, R03BA, 
and R03DC, respectively) if the individual has filled one more prescription of any indicated 
mediations within 24 months. This asthma measure has been previously validated and used in 
population-based observational studies (203, 204).  Additionally, to calculate the average 
daily dose of each type of medication, we divided the total amount of active ingredients of all 
dispensed packages by the total number of days since the date of first asthma diagnosis.  
Parental SES was measured using parental disposable income and education information 
from the LISA database, which is updated on a yearly basis. Disposable income includes 
personal income after tax deduction, study allowance, and other social assistance benefits. To 
make it comparable for families with different sizes and compositions, we calculated the 
disposable income per consumption unit by summing up individual disposable incomes, 
adjusting for consumption units within family, and dividing it into quintiles. Parental 
education was measured as the highest educational level attained between parents and 
 21 
 
grouped as compulsory school (i.e. 9 years of education), high school (10-12 years of 
education), some college (13-14 years of education), and college graduate or higher education 
(≥15 years of education).  
3.3.2 Statistical analysis 
We used Cox proportional hazard models for the following binary outcomes: the first asthma 
diagnosis, at least two dispensed asthma medications (since the first active prescription), an 
inpatient asthma diagnosis, and an outpatient asthma diagnosis. A Cox model is a popular 
statistical model to explore the relationship of various covariates including main exposures 
and lifetime variables of interest of an individual through hazard function. Attained age was 
set as the underlying time scale. Individuals were censored at the date of death, migration, or 
end of the follow-up period (31 Dec 2010). Cumulative hazards for asthma by SES indicators 
were estimated with the Nelson–Aalen method. The proportional hazards assumption was 
tested based on the Schoenfeld residuals as well as by graphical examination. When the 
proportional hazard assumption was violated, we treated parental SES as time (age)-
dependent covariates and time-dependent hazard ratios (HR) were estimated. Estimates 
presented in the study were adjusted for maternal age and marital status during pregnancy, 
child’s gender, parity, healthcare regions, and metropolitan areas. Family clustering was 
taken into account in the models using the robust standard errors.  
In the sub-cohort of children with asthma (≥1 diagnosis or ≥2 medications), we explored the 
associations between parental income and education at the time of first diagnosis/medication 
and average doses of dispensed medication. Linear regression models were used to estimate 
the regression coefficient exp (β) from logarithmic transformed data on daily doses together 
with 95% confidence intervals (CI). Among children with ≥2 asthma diagnoses, we further 
explored the association between time-dependent SES indicators and the risk of inpatient care 
visit after a first asthma diagnosis using Cox models. Time from first diagnosis was set as the 
underlying time scale and the level of previous hospital visit (inpatient/outpatient) was 
adjusted in the model.  
3.4 Studies II & III 
3.4.1 Study population and measures 
Studies II and III were based on two samples within Stockholm County. First, all twins who 
were born in Stockholm County from 1992 and onwards, invited to the CATSS by November 
2011, and completed the neurodevelopmental assessment at the age of 9 or 12 years old 
(n=3,426, response rate 68.8%) were included in Study II. Second, a sub-sample from the 
Stockholm Youth Cohort (SYC) was used as the study base for case and control selections in 
Study III. In the sub-sample, we included children born and living in Stockholm County 
during1993- 2007 with their biological mothers living in Stockholm County one year before 
and one year after the child’s birth (n=277, 478). More detailed information on CATSS and 
the Stockholm Youth Cohort has been provided in previous publications (188, 193). 
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ASD and ADHD in Study II was measured by the Autism-Tics, ADHD, and other 
Comorbidities (A-TAC) inventory, a psychiatric symptom-based telephone interview at the 9 
or 12 years of age (205). A-TAC is accessible online for free and contains 96 gate questions 
to screen childhood ASD, ADHD, and other targeted disorders based on DSM-IV criteria and 
clinical features identified in previous literature and clinical practice. Detailed information on 
the psychometric properties of the A-TAC is provided elsewhere (193, 206, 207). Three 
options of response, “No”, “Yes, to some extent”, and “Yes” were coded as 0, 0.5, and 1.0 
accordingly for each question. We used the lower cutoff value at 4.5 as well as the higher 
cutoff value at 8.5 from the 17-question summed scores to indicate ASD. ADHD lower (at 6) 
and higher cutoff values (at 12.5) were based on the summed scores of 19 ADHD symptoms 
relevant questions. 
Information on ASD in Study III was obtained from all ASD-related services provided by, or 
under contract with the Stockholm County Council. The care-seeking pathways for ASD 
were slightly different from those described for asthma. In Sweden, more than 99% of the 
children receive regular examinations for general health, growth, and developmental 
screening for free at pediatric primary care centers (Barnavårdscentral in Swedish) at 1, 2, 6, 
10-12, 18, 30-36, 48, and 60-72 months of age.  Nurses, general practitioners, and /or 
pediatricians, child psychiatrists, speech therapists, or parents can request for a case referral if 
children present with difficulties of learning, speaking, playing, or other developmental and 
behavioral problems. Then, a comprehensive diagnostic evaluation of suspected ASD is made 
by a specialist team with at least a psychologist and a medical doctor at child pediatric and 
mental health services. Habilitation services, as an additional care-seeking pathway for 
children with ASD, are provided free of charge by the municipality to children with an 
established diagnosis (188). To cover all sources of ASD-related care including the NPR, the 
VAL, the PASTILL, and the HAB, we identified 5,529 ASD cases, with or without presence 
of ID based on ICD and/or DSM codes (ASD: 299 in ICD-9 and DSM-IV, F84 in ICD-10 
and ID: 317-319 in ICD-9 and DSM-IV, F79 in ICD-10 respectively) from Stockholm 
County. We selected a random sample of 20,000 children as controls from the study base, and 
excluded 420 who developed ASD during follow-up. Furthermore, adopted children (n=17), 
multiple births (n=747), births not recorded in the MBR (n=972) from selected cases and 
controls were also excluded.  
Exposure to traffic-related air pollution was estimated using dispersion models incorporating 
the mother’s residential address during pregnancy and the child’s residential address during 
the first year of life for both studies. Additionally, we estimated trimester-specific pollution 
levels during mother’s pregnancy and during child’s 9th year of life in study II. Detailed 
descriptions of the air pollution exposure assessment are available in previous publications 
(140, 208). Briefly, relevant residential addresses were geocoded and pollutant levels 
emanating from road traffic were estimated at these coordinates from dispersion models and 
used to calculate annual average concentrations for NOx and PM10. To account for changes in 
exposure levels among those moving to another residence, time-weighted NOx and PM10 
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concentrations related to road traffic emissions were calculated based on all registered 
addresses during the pregnancy, the child’s first and 9th year of life.  
3.4.2 Statistical analysis 
We used generalized estimating equation models in Study II to account for correlated 
exposure and outcome measures within twin pairs. Odds ratios (OR) and 95% CI for ASD 
associated with a 5
th
 to 95
th
 percentile rising in NOx or PM10 levels were estimated in crude 
models and with adjustment for maternal age and smoking during pregnancy, maternal 
marital status parental education and income, neighborhood deprivation at the year of child 
birth, gender, and parity of the child (209). 
To assess the effect of exposure to pollutants during mother’s pregnancy and child’s first year 
of life on ASD in Study III, we used conditional logistic regression models and conditioned 
on calendar year and municipality of birth. Fixed exposure increments per 20µg/m
3
 for NOx 
and per 10µg/m
3
 for PM10 were used in all models to estimate the risk of ASD outcomes. To 
assess effect modification, we examined the association between exposure to either pollutant 
and subsequent ASD by maternal marital status and smoking during pregnancy, residential 
mobility during mother’s pregnancy, parental education, and neighborhood deprivation at 
child birth, gender, and parity of the child via inclusion of the interaction terms in the 
regression models.  
3.5 Study IV 
3.5.1 Study population and measures 
This nested case-control study was based on data linkage of several Swedish registers via 
unique PIN (210). Briefly, we selected a birth cohort from the MBR including all singletons 
born in Sweden between January 1, 1992 and December 31, 2007 (N=1,579,263) and 
followed them until December 31, 2013, emigration or death. Each person was linked to 
his/her biological mother, father, siblings and cousins through the MGR.  
Inclusion criteria for cases were a primary or secondary diagnosis of ASD from NPR since   
birth. To differentiate between individuals with high and low functioning ASD, we further 
retrieved cases’ diagnoses on ID during the follow-up. ASD and ID definitions were 
consistent with those used in previous studies (188, 211).  
Using an incidence density sampling method, we first selected 10 biologically unrelated 
controls for each case. Second, we selected four types of family members of each case with 
different degrees of genetic relatedness: full-siblings, half-siblings, full-cousins, and half-
cousins from the MGR. All full-siblings born in 1995 or later were eligible as controls. Half-
siblings, full-cousins, and half-cousins were eligible as controls if having the same gender, 
less than 5 years of age difference, being singleton, alive, and ASD-free at the age when the 
case received ASD diagnosis. In case where multiple eligible controls were identified from 
the same extended family, we randomly selected one control for each degree of relatedness.  
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To retrieve information on parental asthma for cases and controls, we used records from any 
of the three registers, i.e. MBR, NPR, and the PDR. In the MBR, a tick-box for asthma/lung 
diseases ever for the mother was indicated at her first antenatal visit from 1992 onwards. In 
the NPR, we used any primary diagnosis of asthma from outpatient visits since 2001 or 
hospitalization records since 1961. In the PDR, dispenses of asthma medications including 
ICS, LTRA, fixed-dose β2-ICS combinations and β2-agonists from July 2005 have been 
previously validated (204) and used as a proxy of asthma diagnosis. Parental asthma was 
categorized as asthma from either parent, maternal asthma, or paternal asthma for analysis.  
Information about asthma medication use during pregnancy was retrieved from two sources, 
i.e. midwife-reported medication use during pregnancy in the MBR since 1995 and all 
dispensed medications from pharmacies recorded in the PDR since July 2005. Two forms of 
β2-agonists were particularly addressed in the study, as systemic β2-agonists (i.e. oral and 
injection) used to be mainly administered to suppress premature labor, while inhaled β2-
agonists were primarily indicated for asthma. We categorized the exposure to asthma, β2-
agonists and other asthma medications into four groups: with asthma but no medications, 
systemic β2-agonists only, inhaled β2-agonists with or without other asthma medications, and 
other asthma medications without any β2-agonists.     
3.5.2 Statistical analysis 
We conducted conditional logistic regression analyses to estimate OR with 95% CIs of ASD 
by parental asthma and asthma medication use during pregnancy. In addition to crude 
models, we also provided estimates adjusted for maternal smoking, BMI, and marital status 
during pregnancy, parents’ countries of birth, parental age and education at child birth, as 
well as the parity of the child. First, the association between parental asthma and offspring 
ASD overall, with and without ID was estimated using cases and unrelated controls. Second, 
we performed separate analyses using cases and their half-sibling, full-cousin and half-cousin 
controls. This allowed us to account for unmeasured familial confounding factors shared by 
cases and their relatives as well as measured confounders and mediators mentioned above. 
Full-sibling controls sharing the same parents with cases were not included here. Third, to 
investigate the association between prenatal exposures to β2-agonists, and other asthma 
medications during pregnancy with subsequent ASD, we restricted the sample to children 
born to mothers with asthma from 1995 due to medication data availability. ASD cases were 
compared to unrelated and sibling controls, with not exposed to any asthma medications as 
the reference group.  
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4 Main results and interpretations  
4.1 Study I 
4.1.1 Results 
In a birth cohort of 211,520 children, we found a consistently positive association for parental 
education and a time-dependent association for parental income with preschool asthma.  
Children of parents with lower education were at higher risk of asthma (measured by ≥ 1 
diagnosis or ≥ 2 medications) regardless of age. In contrast, children of parents with the 
lowest compared to the highest income were at higher risk of asthma during the first year of 
life, but lower risk after the first year of life (Figure 1 in paper 1).  
Among 13,990 children diagnosed with asthma within the birth cohort, less than 70% had at 
least one package of ICS dispensed and 21-23% had LTRA dispensed (Figure 8). No 
difference in average dose of dispensed controller medications by parental income was 
observed. However, the average doses were significantly lower among children of parents 
with lower education compared to those of parents with highest education (Figure 4 in paper 
1). 
 
Figure 8. Frequency of medication consumption among children diagnosed with asthma from 
different SES groups. 
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4.1.2 Interpretation 
Most results were consistent with prior literature on parental education and the risk of 
childhood asthma. For example, a cross-sectional study from Denmark and two studies from 
the Netherlands demonstrated a similarly increased risk (23%-53%) of asthma associated 
with lower parental education levels (48, 212, 213). Several pathways including exposure to 
household allergens, traffic-related air pollution, tobacco smoke, maternal stress, as well as 
maternal obesity may partially explain the association (214-217). However, the temporal 
effect of parental income on preschool asthma is much less described. The Generation R 
study reported a time-varying effect on wheezing symptoms by parental income but in quite 
the opposite direction from what we observed. They reported a positive association of 
parental income and preschool wheezing at age one and a negative association at age 3-4 
(213). The discrepant findings could possibly be explained by their self-reported parental 
income measures at two years of age, wheezing symptoms rather than asthma diagnosis, and 
different covariate adjustment. For example, breastfeeding behavior, which is a time-
dependent covariate, was adjusted for in their study but not in ours (213). The prevalence of 
transient wheezing also peaks before three years of age, which could possibly explain the 
increased risk seen in their study (218). 
Furthermore, our finding that children with lower parental education have lower controller 
medication (i.e. ICS and LTRA) dispensing rates was consistent with previous findings (219). 
Therefore, we speculate that children of parents with lower education may not be sufficiently 
surveilled and followed up after initiating the use of controller medications (220). 
4.2 Studies II & III 
4.2.1 Results 
The distribution of NOx and PM10 levels during pregnancy, child’s first, and the 9
th
 years of 
life are presented in Table 3 using samples from the CATSS and the SYC. We observed 
decreases of 10-15% in average levels of NOx between pregnancy and the child’s first year of 
life in both studies. Furthermore, average NOx levels dropped from 12.69 to 5.40 µg/m
3 
during a10-year observation period for CATSS. On the other hand, average levels of PM10 
remained relatively constant over the study period in both studies.  
We did not find any evidence of an association between NOx and PM10 levels during the 
prenatal and postnatal period and subsequent ASD and ADHD symptoms in CATSS, or with 
ASD clinical diagnosis in SYC (Figure 9). Furthermore, no difference was observed based on 
low and high cutoff values of ASD and ADHD symptoms, or the comorbidity of ASD with 
ID. Among children from SYC, a significant interaction of pollutant levels with 
neighborhood deprivation and residential mobility was observed (Table 4). There was a 
suggested inverse relationship between exposure to NOx and PM10 with ASD overall for 
those in the most deprived neighborhoods. A decreased odds for ASD overall with exposure 
to NOx and PM10 pre- and postnatally was seen among those whose mothers changed their 
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residential address during pregnancy (p values for all interactions<0.03). However, these 
interaction effects were not observed for ASD with ID. 
Table 3. Distribution of estimated average NOx and PM10 levels based on samples from 
CATSS and SYC. 
  Mean, SD 5
th
 - 95
th
 percentile Median 
CATSS (n=3,426)     
Pregnancy NOx 12.69±10.94 1.49-34.53 9.00 
 PM10 4.19±3.10 0.58-9.38 3.34 
First year of life NOx 10.78±9.49 1.26-30.59 7.60 
 PM10 3.85±2.90 0.54-9.04 3.06 
Ninth year of life NOx 5.40±4.83 0.70-15.75 3.98 
 PM10 3.26±2.63 0.50-8.23 2.58 
     
SYC (n=23,373)     
Pregnancy NOx 11.04±11.39 1.23-30.27 7.80 
 PM10 4.38±3.22 0.60-9.98 3.65 
First year of life NOx 9.83±10.33 1.09-27.10 6.93 
 PM10 4.21±3.14 0.60-9.79 3.48 
 Figure 9. ASD risk by NOx and PM10 levels during prenatal and postnatal period. 
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Table 4. Association between NOx and PM10 levels during pre- and post-natal period and risk of ASD stratified by neighborhood deprivation and 
residential mobility in the SYC cohort. Models were conditioned on birth year and municipality and adjusted for maternal marital status during pregnancy, 
parental countries of birth, parental age, income, education, employment, and neighborhood deprivation at child birth, gender, birth month, and birth order 
of the child. 
  NOx levels PM10 levels 
  ASD overall ASD with ID ASD overall ASD with ID 
  OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Overall Pregnancy  0.91 (0.86, 0.97) 1.06 (0.89, 1.26) 0.86 (0.77, 0.95) 1.03 (0.74, 1.42) 
 First year of life  0.90 (0.85, 0.97) 1.08 (0.88, 1.32) 0.86 (0.77, 0.96) 1.04 (0.73, 1.49) 
      
Stratified by neighborhood deprivation at the year of child birth 
Least deprived neighborhood Pregnancy      
 First year of life  0.97 (0.87, 1.08) 0.99 (0.73, 1.33) 0.96 (0.80, 1.16) 0.94 (0.55, 1.62) 
Intermediate deprived neighborhood Pregnancy  0.97 (0.86, 1.10) 1.09 (0.77, 1.55) 0.97 (0.80, 1.18) 1.12 (0.62, 2.02) 
 First year of life  0.93 (0.86, 1.00) 1.03 (0.82, 1.28) 0.86 (0.73, 1.00) 1.02 (0.65, 1.58) 
Most deprived neighborhood Pregnancy  0.93 (0.85, 1.01) 1.08  (0.86, 1.36) 0.86 (0.74, 1.01) 1.07 (0.68, 1.70) 
 First year of life  0.80 (0.67, 0.95) 1.31 (0.94, 1.83) 0.81 (0.64, 1.03) 1.21 (0.74, 1.99) 
  0.77 (0.63, 0.94) 1.16 (0.75, 1.81) 0.82 (0.65, 1.05) 1.06 (0.62, 1.82) 
Stratified by residential mobility during mother’s pregnancy 
Non-movers Pregnancy  0.94 (0.88, 1.00) 1.08 (0.90, 1.30) 0.93 (0.83, 1.04) 1.05 (0.74, 1.48) 
 First year of life  0.96 (0.89, 1.03) 1.14 (0.92, 1.41) 0.94 (0.84, 1.06) 1.08 (0.75, 1.57) 
Movers* Pregnancy  0.79 (0.68, 0.91) 0.97 (0.70, 1.34) 0.57 (0.44, 0.74) 0.95 (0.51, 1.77) 
 First year of life  0.71 (0.60, 0.83) 0.79 (0.50, 1.23) 0.60 (0.47, 0.78) 0.85 (0.44, 1.62) 
*Movers were defined by the frequency of the mother changing her residential address during pregnancy.
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4.2.2 Interpretation 
We acknowledge that NOx and PM10 levels were relatively low in Stockholm County, 
compared to other study settings which included Taiwan, California and other U.S. states 
(123, 124, 126, 127, 144). The substantial reduction of NOx levels is mostly attributed to the 
increased use of catalytic converters on vehicles. The smaller reduction of PM10 levels 
observed in both studies may be due to the largely constant background concentrations 
generated from long-distance transport and relatively small variations on concentrations 
generated from local traffic (221).  
In contrast to the growing body of literature from the U.S. showing a positive relationship 
between air pollution and NDDs (123, 124, 126, 127), no clear association was observed in 
data from Stockholm County nor other European cohorts (i.e. three cohorts from Spain, one 
from Italy and one from the Netherlands) (125). Null results remain in the analyses even after 
adjusting for community and family SES-related factors including parental income and 
education, maternal marital status and country of birth as well as in subgroup-specific 
analyses. However, residual confounding by parental psychiatric health, moving patterns, and 
unmeasured indicators for SES during pregnancy and early infancy and the relatively low 
proportion of ASD cases with ID may still have contributed to the null findings. 
4.3 STUDY IV  
4.3.1 Results 
We found a slightly increased risk of offspring ASD with maternal asthma and a weaker, 
moderate, but significantly increased risk with paternal asthma when comparing cases and 
unrelated controls from the selected birth cohort. In further comparisons between cases and 
their half-siblings, full-cousins, and half-cousins, the association between maternal, but not 
paternal, asthma and offspring ASD remained (Figure 10).  
To further explore whether the association of maternal asthma and offspring ASD was 
mediated through asthma medication use during pregnancy, we used the sub-sample of 
children born to mothers with asthma or mothers who used asthma medications. We observed 
no association between prenatal exposure to any indicated asthma medications or systemic 
β2-agonists with offspring ASD when comparing cases with unrelated controls, and with full-
siblings (Figure 11).  
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Figure 10. Adjusted ORs of ASD in offspring by maternal and paternal asthma. 
 
 
Figure 11. Adjusted ORs of ASD in offspring by asthma medication during pregnancy 
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4.3.2 Interpretation 
Our findings on maternal asthma and offspring ASD were mostly in line with findings from a 
case-control study from North California, the U.S. and a cohort study from Australia (117, 
118), but not with those of the recent case-control study from California (i.e. the CHARGE 
study) {Lyall, 2014 #106;Hertz-Picciotto, 2006 #353}. First, characteristics of cases in 
studies might explain the discrepancy.  In the original CHARGE study, cases with full 
syndrome autism, but not spectrum disorders, were identified through the California 
Department of Developmental Services and asked to be participants {Lyall, 2014 #106;Hertz-
Picciotto, 2006 #353} whereas we and the other two studies ascertained all ASD and ID cases 
from the national or regional registers (117, 118). Second, the average age at the end of 
follow-up was 10 or 15 years in the current study and the Australian study (118). Study 
participants in both case-control studies from California were on average below 5 years of 
age at enrollment (115, 117). Controls, who are still at risk of developing full syndrome 
autism but not followed, might also contribute to discrepancy. Third, selection criteria of 
eligible controls from the source population were different in the two case-control studies 
from California, respectively. Being ASD free was the only criteria in the North California 
study and the current study (117). In the CHARGE study, controls were not allowed to have 
any early learning difficulties or other behavioral symptoms (115).  
Associations between paternal asthma and offspring ASD were less reported previously and 
with limited statistical power (130, 156). The smaller effect of paternal asthma and further 
dilution of the association in half-sibling and cousin analyses suggests the effect of paternal 
asthma can be confounded by familial factors.  
Two previous human studies from the U.S. reported a positive association on continuous 
treatment with terbutaline (a β2-agonist) in utero and risk of subsequent ASD (122, 170). One 
study suggested that the association between maternal asthma and offspring ASD was not 
explained by β2-agonists treatment during pregnancy(122), suggesting a possibility of 
confounding by indication. The results from the second study should be interpreted with 
caution due to limited number of observations, characteristics of the study population, and the 
indication and duration of β2-agonist treatment (170). Therefore, firm conclusions concerning 
the safety of β2-agonists during pregnancy cannot be drawn based on current evidence. 
Furthermore, previous studies did not support any increased risk of NDDs in children 
exposed to ICS in utero (222, 223), which is in line with our findings. We therefore do not 
consider the mechanism linking maternal asthma and offspring ASD to be through asthma 
medication use during pregnancy.  
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5 GENERAL DISCUSSION 
This thesis comprises four observational studies on risk factors for asthma and ASD in 
children using different study designs. The current chapter provides some important 
considerations on the internal (i.e. design, measurement errors, and confounding) and external 
validity (generalizability) of the studies. 
5.1 Study designs 
Although randomized experiments are often considered the gold standard in estimating causal 
effect and avoiding bias, they may be infeasible in some conditions due to economical, 
ethical, or time (e.g. long-term outcomes) constraints. Therefore, the Swedish registers 
provide rich data sources to investigate important research questions and can be used in 
different observational study designs. Furthermore, no recruitment process is needed 
comparing to average cohort studies or RCT, eliminating the potential risks of selection and 
drop-out bias.  
The cohort design can be either prospective or retrospective. In a prospective cohort like 
study I, more than two groups of individuals are categorized based on their parental SES, 
followed over time, and compared for the incidence of asthma. In retrospective cohorts (e.g. 
study II), information on outcomes has been recorded in the registers and recall bias can be 
eliminated. The case-control designs, as in study III allow rare outcomes such as ASD to be 
studied. Two groups of people with and without ASD are sampled from the general 
population or specific sub-population and compared for the occurrence of exposure. The 
nested case-control study (e.g. study IV) is simply designed as a case-control study nested 
within a population cohort. Unlike a classical case-control design, this sampling method 
involves selection of controls from a dynamic population, which allows time-varying 
incidence of the cases. In addition, the odds ratio estimates may be closer to the hazard ratio 
estimates from cohort analysis (224).  
The cohort, case-control, and nested case-control designs, however, are still subject to 
potential biases due to some residual or unmeasured confounding factors. Therefore, family-
based designs such as study IV, take advantage of sub-samples from a larger population in a 
more informative way and account for some genetic and/or environmental confounding in 
analyses. For instance, comparing cases with full-siblings who share on average 50% of the 
segregating genes can help rule out some potential genetic confounding effect based on the 
observed association at population level. However, it should be noted that such designs are 
based on specific assumptions which could cause limitations in the interpretation of the 
finding and generalizability. For example, the sibling- and cousin-control designs assume the 
carry-over effect (i.e. the possibility of being exposed to asthma medications in the older 
sibling can influence the possibility of being exposed again and the ASD outcome in the 
younger sibling) (225). 
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5.2 Random and systematic error  
Measurement error is an inevitable issue in epidemiological studies. Random errors are 
usually a result of chance and affect the precision of the risk estimation depending on study 
sample size. It is important to note that the 95% confidence interval estimates include a 5% 
chance of random error and are estimated without accounting for known and unknown 
systematic errors. Systematic errors include deviations of the results that are not introduced 
by chance, but by a repeated inaccurate measurement of either the outcomes or exposures, or 
perhaps a covariate. The internal validity of an observed association in a study is often 
affected by systematic error. Three common sources of systematic error are selection bias, 
information bias, and confounding. 
5.2.1 Selection bias  
In studies I and IV, asthma and ASD were defined by at least one relevant diagnosis from the 
NPR, which includes all inpatient and approximately 80% of the outpatient records. The 
narrow definitions of asthma and ASD did not include cases diagnosed at primary healthcare 
centers. Outcomes could therefore have been underestimated if case ascertainment did not 
embrace all asthma and ASD cases, especially the ones with milder symptoms. If such bias 
was present, the risk estimate would be biased toward the null. However, the measurement of 
asthma by at least two relevant medications from the PDR without a confirmed diagnosis 
from the NPR in study I can be viewed as an evaluation of such bias in the absence of 
primary healthcare data.  In study II, we included Stockholm-born twins whose parents 
participated in the CATSS, representing 70% of the population from the original sample. The 
response rate probably affected the precision of association estimates and pushed the 
association towards null.  The difference in response rates between respondents and non-
respondents is a limitation for the accurate ascertainment of ASD and ADHD cases, therefore 
creating potential selection bias. In studies III and IV, bias on ASD case ascertainment was 
minimized by combining data sources of ASD-related healthcare services within Stockholm 
County and by comparing cases with their family members.   
5.2.2 Information bias  
Information bias is often a measurement error (called misclassification) of an exposure or 
disease outcome during the process of data collection, due to inaccurate information recall, 
use of sub-optimal measurement methods, or other reasons. Misclassification can be 
differential and non-differential depending on whether the misclassification of the exposure is 
related to the outcome, or vice versa.  
In a previous validation study, our colleagues showed that 26% of preschool children with 
asthma medications had a diagnosis of bronchitis/bronchiolitis rather than asthma (204). 
Thus, asthma should be defined in a more rigorous way by including at least one diagnosis of 
asthma and at least two dispensed medications in children of this age group. This indicates 
that misclassification of asthma using either diagnosis or medications in study I may be 
present and lead to a potential underestimation of a true association.  
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ASD and ADHD definitions in studies II and III have been tested and confirmed with high 
sensitivity and specificity in a previous validation study (188, 205). However, the 
measurement of traffic-related air pollution levels based on residential address in studies II 
and III is likely to induce some misclassification bias on the exposure levels for NOx and 
PM10. In study III, nearly 20% of mothers or young parents changed their addresses during 
pregnancy and child’s early life and were accordingly exposed to different levels of air 
pollution. When reporting the subgroup-specific associations, we observed an inverse 
association for air pollution and subsequent ASD among movers. This has to be interpreted 
with caution as moving patterns might have influenced the classification of some confounders 
(e.g. municipality). Furthermore, misclassification of ASD outcomes may be present due to 
the loss of follow-up among some older children who migrated from Stockholm County after 
being enrolled in the cohort. However, consistent results were observed in a subgroup of 
children born after 2003. In study IV, the asthma/lung disease tick-box from the MBR was 
used as one source of maternal asthma measurement. Misclassification bias might have been 
introduced by including other lung diseases such as chronic obstructive pulmonary disease 
and pneumonia, although they are less common in young adulthood. In the case of such 
misclassification, it should be non-differential and could push estimates towards the null as 
the mothers would not have chance to report their lung disease differently in relation to later 
offspring ASD. However, the sensitivity analysis confirmed that the potentially less accurate 
measures of maternal asthma based on MBR tick-box information did not change the 
estimates.  
5.2.3 Confounding 
Acknowledging and adjusting for confounding is crucial for reported associations in 
epidemiological studies (226). In the presence of confounding, the estimate of an association 
between an exposure and a disease outcome can be inaccurate or even spurious without 
proper adjustment for confounders. As demonstrated in the method section, causal diagrams 
have been widely applied to identify potential confounders a priori for the statistical 
modelling. However, unmeasured or residual confounding can still be present in each study. 
For example, the genetic confounding for the association between parental SES and 
preschool asthma in offspring was not taken into consideration in study I. In studies II and III, 
although SES confounders including parental income, education, and maternal marital status 
have been adjusted for in the analysis, residual confounding still seemed to exist in the 
observed inverse association among movers as well as those from the most deprived 
neighborhood. In study IV, as illustrated in Figure 7, the potential bias generated from 
unmeasured familial (genetic and shared environment) confounding has been noted. The 
analysis comparing cases with unrelated controls indicated that paternal asthma is associated 
with a weak but significant increased risk of offspring asthma. However, the association 
disappeared when comparing cases with sibling and cousin controls, suggesting most of the 
risk from the paternal side is instead attributable to familial confounding.  
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5.3 Generalizability 
Generalizability refers to the relevance of findings based on a source population to other 
populations at other places (226). Although the population and characteristics, inclusion and 
exclusion criteria, as well as lengths of follow-up vary for each study in the thesis, the results 
in each study are overall generalizable at the population level since the original large samples 
are quite representative of the Swedish population. Specifically, the null associations of air 
pollution and ASD have been replicated in twins and singletons living in Stockholm, as well 
as children of similar age in other European cohorts (125). 
5.4 Ethical consideration 
According to the Swedish ethical review act (SFS no 2003:460), all studies with the intention 
to interact with research participants physically or mentally must be reviewed by an ethical 
board before initiation of the project. The participants in register-based research are involved 
in a different way, as their information is not directly collected by researchers but by third 
parties, such as governmental agencies. This also means sensitive information can be 
gathered and analyzed by researchers without notifying participants. To protect the integrity 
of personal data, ethical approval is needed for all epidemiological research to clarify the 
potential value of generated knowledge and minimize the risk of breaching the data integrity. 
The data should be used for the specific research purpose and there should be no direct 
contact with participants. Researchers should also manage other potential risks generated 
from combining too detailed information on participants (227). However, in the case that 
researchers need to contact and recruit specific sub-population (e.g. twins) for additional data, 
informed consent is required. If participants are younger than 15 years of age, both children 
and their parents should be informed prior to participation and give the consent.  
All studies included in this thesis have been approved by the regional Ethical Review Board 
in Stockholm. None of the studies directly involved with study participants. More 
specifically, studies I, III, and IV used large population-based register data, meaning that 
informed consent was not required. To protect the personal integrity of all participants, the 
PINs are encrypted and replaced by random sequence numbers. For study II, informed 
consents were previously collected from both parents and children according to the 
Declaration of Helsinki. 
5.5 Concluding remarks 
The population-based and genetically informed designs allowed me to further understand the 
risk factors of asthma and ASD in children, expanding upon rather than replicating the 
findings from prior research. In particular, an age-dependent effect on offspring asthma by 
parental income is observed, a consistently increased risk of incident asthma, and reduced 
use of controller medications among children of parents with lower education (Study I). 
There seems not to be an association between traffic-related air pollution exposure during 
fetal and early life and subsequent ASD (Studies II & III). Furthermore, maternal asthma 
is associated with increased risk of offspring ASD, which is neither confounded by familial 
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factors shared in siblings and cousins, nor mediated by use of asthma medication during 
pregnancy (Study IV). 
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6.2 Future perspectives 
In study I, we have addressed the association between parental SES and preschool asthma 
using a population-based cohort design. From the etiological perspective, others have 
reported that childhood asthma is affected by environmental and perinatal factors including 
smoking during pregnancy, fetal growth, and infections, which possibly act as mediators of 
the observed associations (22, 195, 215, 228). One way to address the question further is to 
explore the possible pathways through such variables. Another way is to explore the effect of 
other measures of SES including the neighborhood deprivation, occupation, and employment 
dynamics, as the current study only takes into consideration parental income and education. A 
third way to further investigate the association could be to include other asthma phenotypes 
as outcomes including later-onset, transient, and persistent asthma cases and the comorbidity 
with other allergic diseases. From the clinical perspective, the observed patterns of dispensed 
controller medication by parental education among diagnosed children need to be 
investigated for further explanations. Improved understanding of their phenotypes, asthma 
severity, comorbidity, surveillance and follow-up of parental asthma-related knowledge is 
needed for a better clinical management.  
Ambient air pollution, specifically traffic-related air pollution, is a global public health issue 
(136, 138). Policy decisions regarding air pollution and health should be made with deliberate 
consideration based on evidence from specific scientific research studies. The evidence of an 
increased risk of ASD by elevated NOx and PM10 levels is not obviously seen within 
Stockholm County. Careful adjustment for a constellation of confounding factors including 
SES, genetic susceptibility, and area related factors such as population density, deprivation, 
noise should be encouraged in future studies. Population-based case-control studies and 
within-family designs will be useful tools to further investigate other neurodevelopmental 
effects by exposure to air pollution. Additionally, based on the evidence on   pathological 
changes in central nervous system caused by chronic air pollution from human, animal and 
cell samples, the long-term effect of NOx and PM10 as well as other air pollution components’ 
effect (e.g. ozone, PM2.5 and PM0.1) can be of interest (229). 
Up to 45% of women with asthma experience symptom exacerbations during pregnancy 
(230). This subgroup of patients is also at increased risk of adverse obstetric and birth 
outcomes, as well as other long-term health outcomes including ASD in offspring. The main 
findings of study IV suggest a potential causal association between maternal asthma and 
offspring ASD. However, the biological mechanisms remain unclear. Furthermore, a 
substantial proportion of women are still under suboptimal treatment despite the existence of 
clinical guideline on how to manage asthma during pregnancy (231). It is therefore worth 
investigating whether there is a dose-response relationship between asthma severity and 
management with the risk of subsequent ASD. Last but not least, more studies are needed on 
the safety of asthma medication use during pregnancy particularly intervention studies of 
high quality to improve asthma management during pregnancy.  
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